Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

EAU 2024: Membranous NECTIN-4 Expression in Metastasis Versus Matched Primary Tumor More Accurately Predicts Enfortumab Vedotin Response EAU 2024: First-Line Maintenance Therapy ... Atezolizumab + ...

It is formulated as solution for intravesical route of administration. Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive ...

whose tumors express PD-L1 (combined positive score [CPS] ≥1.Keytruda is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive ...

Here, we study the effects of peritoneal Bacillus Calmette–Guérin (BCG) administration to find TI-mediated protection in the spleen against a subsequent heterologous infection by the Gram-negative ...

This important work advances our understanding of trained immunity, especially in the context of Bacillus Calmette-Guérin (BCG) administration and host-pathogen interactions. The evidence supporting ...

NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025 for its innovative treatment targeting Bacillus Calmette-Guérin ...

Sources: About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance ... indicated with Bacillus Calmette-Guérin ...